Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05048758
Other study ID # GRK2350-B5-P2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 22, 2021
Est. completion date January 17, 2024

Study information

Verified date March 2024
Source Central Institute of Mental Health, Mannheim
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Adverse childhood experiences (ACE) and their relation to the development of an alcohol use disorder (AUD) will be measured with functional magnetic resonance imaging (fMRI).


Description:

The aim of this study is to examine the impact of ACE on stress sensitivity, cue-reactivity, and emotion processing in individuals with AUD at a longitudinal level. For this, participants (excluding healthy controls) from the first project (see https://clinicaltrials.gov/ct2/show/NCT03758053) will be re-examined after 2 to 2.5 years to explore the involvement of these mechanisms in relation to (long-term) relapse risk, which is a central issue in substance use disorders. Furthermore, we will investigate cognitive functions, specifically response inhibition and working memory, in the relationship between ACE and AUD. Additional participants may be recruited to mitigate sample attrition from the first project and to achieve the desired sample size. To assess cognitive functions and data from new participants in relation to relapse risk, we will perform a 3-month follow-up. Neural correlates of stress-sensitivity, emotion processing, alcohol cue-reactivity and cognitive functions will be assessed using fMRI. Furthermore, blood and saliva samples will be used to assess biological and physiological mechanisms (e.g. salivary cortisol level or genetic markers of AUD and possible gene-environment-interactions). The current project is interested in the extent to which ACE severity modulates neural activation in specific brain regions during the execution of fMRI paradigms as well as alcohol-related measures (e.g., craving and alcohol consumption). Of particular interest is the question whether these neural and alcohol-related measures are associated with relapse risk. 55 individuals with AUD and varying levels of ACE will be examined using interviews, questionnaires, fMRI tasks as well as saliva and blood samples. Update from 29/03/2023: the relationships of interest will be examined using a dimensional approach to the predictor variable (ACE). Thus, participants will not be divided into two groups (no or mild ACE vs. moderate to severe ACE) as originally planned, but will instead be treated as one group with varying levels of ACE. The new sample size (n = 55) is based on an updated sample size calculation for a linear regression (two-tailed) using the following input parameters: f² = 0.15 (moderate effect size), alpha error = 0.05, and power = 80%. All ethical votes and informed consents of participants will be obtained according to the declaration of Helsinki.


Recruitment information / eligibility

Status Completed
Enrollment 43
Est. completion date January 17, 2024
Est. primary completion date January 17, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Male and female - Age between 18 and 65 - Normal or correctable eyesight - Sufficient ability to communicate with the investigators, to answer questions in oral and written form - "Fully Informed Consent" - "Written Informed Consent" - Individuals with alcohol use disorder according to DSM-5 or 'heavy drinking' (alcohol intake > 40g/ more than 5 days (women) & 60g/ more than 5 days (men) and varying levels of adverse childhood experiences Exclusion Criteria: - Withdrawal of the declaration of consent - Exclusion criteria for an MRI scan (pregnancy, metal implants, etc.) - Severe internal, neurological and psychiatric comorbidities - Pharmacotherapy with psychoactive substances within the last 14 days (except treatment with SSRI/SNRIs for at least 28 days) - Axis-I disorder according to ICD-10 and DSM 5 (except tobacco and alcohol use disorder, substance abuse with less than 2(11) criteria according to DSM-5, mild depressive episode, adaptation disorder and specific phobia within the last 12 months) - Positive urin drug screening (cannabis, amphetamine, opiates, benzodiazepines, cocaine) - Withdrawal symptoms (CIWA-R > 7) - Intoxication at time of investigation (breathalyzer > 0.3‰) - Suicidal tendency or potential danger for others

Study Design


Intervention

Other:
No intervention
No intervention

Locations

Country Name City State
Germany Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit Mannheim Baden-Württemberg

Sponsors (2)

Lead Sponsor Collaborator
Central Institute of Mental Health, Mannheim German Research Foundation

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Stress-sensitivity Stress-sensitivity: Imaging Stress Task to assess neural activation patterns during mental arithmetic tasks with negative feedback fMRI measurement at one day only (day of fMRI experiment)
Primary fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Emotion processing Emotion-processing: emotional face-/form-matching task to assess neural activation patters of emotion processing fMRI measurement at one day only (day of fMRI experiment)
Primary fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Alcohol cue-reactivity Alcohol cue-reactivity: pictures of alcoholic beverages to assess neural alcohol-cue reactivity fMRI measurement at one day only (day of fMRI experiment)
Primary fMRI to assess group differences in task-specific brain activation patterns: Response inhibition Response inhibition: Stop Signal Task (variation of go/no-go) to assess response inhibition. fMRI measurement at one day only (day of fMRI experiment)
Primary fMRI to assess group differences in task-specific brain activation patterns: Working memory Working memory: n-back task (continuous performance) to assess working memory function. fMRI measurement at one day only (day of fMRI experiment)
Primary Long-term alcohol consumption Self-report in longitudinal sample measured with the LDH interview 2 - 2.5 year follow-up after first project
Primary Short-term alcohol consumption Self-report in whole sample measured with the Form 90 interview 3-month follow-up after current project
Secondary Hormonal stress response using salivary cortisol level Collection of saliva on a subject's regular week-day for the individual's normal cortisol awakening response and circadian rhythm (basal hypothalamic-pituitary-adrenal-function at 0, 0.5, 8 and 14 hours after wake-up).
Cortisol awakening reaction, area under the curve and slope will therefore be calculated [nmol/L]
Normal awakening response on a subject's regular week-day (0, 0.5, 8 and 14 hours after wake-up)
Secondary Hormonal stress response using salivary cortisol level Time course of salivary cortisol level. Area under the curve and slope will be calculated [nmol/L] day of fMRI experiment, at -45, -22, -10 minutes before and 35, 45, 60, 75 and 90 minutes after onset of stress induction
Secondary GWAS and especially glutamatergic, serotonergic single-nucleotide polymorphisms Genomic DNA using 40ml EDTA-blood Blood sample at one day only (day of fMRI experiment)
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A